BPMC Company Profile and Key Details

Q: Who are the executives of BPMC?

Ms. Debra Durso-BumpusChief People OfficerDr. Percy H. Carter M.B.A., Ph.D.Chief Scientific OfficerJenna CohenSenior Director & Head of Investor RelationsMr. Michael LandsittelChief Financial OfficerMr. Alexis A. Borisy A.M.Founder & Executive Chairman of Board of DirectorsMs. Tracey L. McCain Esq.Executive Vice President, Chief Legal & Compliance Officer and Sec.Mr. Jeffrey W. Albers J.D., M.B.A., MBAExecutive ChairmanMs. Christina RossiChief Operating OfficerDr. Christopher K. MurraySenior Vice President of Technical OperationsDr. Christopher K. Murray Ph.D.Senior Vice President of Technical Operations and Chief Technical Operations & Quality OfficerMs. Ariel HurleySenior Vice President, Fin. & Principal Accounting OfficerMs. Kathryn HavilandPres, Chief Executive Officer & Director

NASDAQ : BPMC

Blueprint Medicines

$129.46

0.18+0.14%

Open: 4:00 PM

Not Actively Trading

62.9

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Blueprint Medicines Corporation (BPMC) stock surged +0.14%, trading at $129.46 on NASDAQ, up from the previous close of $129.28. The stock opened at $129.46, fluctuating between $129.46 and $129.46 in the recent session.

Stock Snapshot

129.28

Prev. Close

8.36B

Market Cap

129.46

Day Low

-51.57768924302789

P/E Ratio

-2.51

EPS (TTM)

-7.44

Cash Flow per Share

129.46

Open

64.58M

Number of Shares

129.46

Day High

92.91%

Free Float in %

2.14

Book Value

2.98M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 17, 2025	129.35	129.55	129.30	129.46	2.93M
Jul 16, 2025	129.34	129.65	129.20	129.28	25.27M
Jul 15, 2025	129.33	129.40	129.31	129.35	5.12M
Jul 14, 2025	129.30	129.47	129.25	129.36	6.67M
Jul 11, 2025	129.32	129.35	129.00	129.30	3.48M
Jul 10, 2025	129.49	129.49	129.23	129.33	5.98M
Jul 09, 2025	128.47	128.58	128.35	128.55	3M
Jul 08, 2025	128.37	128.78	128.31	128.40	2.96M
Jul 07, 2025	128.31	128.44	128.22	128.40	1.86M
Jul 03, 2025	128.25	128.40	128.20	128.35	1.35M
Jul 02, 2025	128.35	128.45	128.20	128.20	2.28M
Jul 01, 2025	128.18	128.52	128.16	128.34	2.59M
Jun 30, 2025	128.30	128.32	128.08	128.18	2.35M
Jun 27, 2025	128.24	128.28	128.06	128.11	2.8M
Jun 26, 2025	128.29	128.31	128.10	128.15	2.47M
Jun 25, 2025	128.30	128.32	128.19	128.25	2.44M
Jun 24, 2025	128.40	128.40	128.15	128.26	3.38M
Jun 23, 2025	128.19	128.45	128.11	128.40	3.41M
Jun 20, 2025	128.27	128.30	128.00	128.20	4.49M
Jun 18, 2025	128.29	128.32	128.02	128.12	3.48M

Contact Details

Cambridge, MA 02139

United States

https://www.blueprintmedicines.com 617 374 7580

About Company

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

Blueprint Medicines Corporation (NASDAQ:BPMC) closed at $129.46 USD, gaining $0.18 (0.14%) from the previous close of $129.28. The stock is currently trading near its 52-week high $73.04 and $129.55. With a market capitalization of about $8.36 billion, Blueprint Medicines Corporation is classified as a mid-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 3.29 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Blueprint Medicines Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kathryn Haviland, the company employs approximately 682 people and listed since April 30, 2015. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.67%, SMA50 9.56%, SMA200 30.2%). The stock’s 14-day RSI is 76.66 (overbought), while the ATR of 0.85 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -0.15% below its high and over 77.25% above its low.

Valuation Metrics

Blueprint Medicines Corporation trades at a P/E ratio of -166.47, slightly below the S&P 500 average, with a price-to-sales ratio of 28.27 and a price-to-book ratio of 24.07 reflecting a rich premium to book value. The P/FCF stands at -96.54, also below market averages. Compared to sector medians, Blueprint Medicines Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Blueprint Medicines Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $46.94. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Blueprint Medicines Corporation generated EPS of -$2.46 over the past year. Five-year average earnings growth is 31.87%. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$0.47. Next year's EPS is expected at $34.45. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $135.00 to $129.00. The high target offers 4.28% upside. The low target suggests -0.36% downside. The mean target is $130.50. This offers 0.8% upside. Blueprint Medicines Corporation earnings surprise history is a mixed track record. The quarter that ended May 01, 2025, missed forecasts by 76.19%. The prior quarter beat by 16.18%. Over the last six quarters, Apple has recorded several small beats. These include -10.78% in February 15, 2024.

Shareholding & Insider Activity

Blueprint Medicines Corporation has 64.58 million shares outstanding. The public float is 60.00 million shares, elevated short interest at 5.45% of float. This equals 3.13 million shares. The short ratio is 0.62 days. Institutional investors hold 110.85% of the float. Insiders own 0.87%. Haviland Kate holds 165.93 thousand shares, Albers Jeffrey W. has 146.63 thousand shares and Namouni Fouad has 75.78 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Blueprint Medicines generated $249.38M in revenue, or $4.12 per share. Gross margin was 90.19%, operating margin -194.99%, and net profit margin -203.30%. Returns are negative, with ROA at -48.32% and ROE at -388.17%.
On valuation metrics, Blueprint Medicines trades at a P/E of -166.47, P/S of 28.27 and P/B of 24.07. The current ratio is 2.80 and quick ratio is 2.75. Operationally, the company’s inventory turnover is 0.79 and cash conversion cycle is 531.28 days. Debt-to-equity is 0.36, supported by a cash flow-to-debt ratio of -0.68.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Blueprint Medicines posted revenue of $249.38M, down slightly from $204.04M in the prior quarter. Gross profit was $224.92M (margin 90.19%). Operating income was - $486.28M (margin -195.0%). Net income was- $506.98M (EPS - $8.37).
The company ended the quarter with $710.64M in cash and short-term investments, a total debt of $774.12M, and net debt of $702.84M. Total assets were $1.05B, with equity of $130.61M. Financials further reflected weakness, with operating cash flow of - $436.85M, free cash flow of - $452.91M, and capital expenditures of - $16.06M.

Price Forecast & Outlook

Our AI price prediction model suggests that Blueprint Medicines Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.63%, with price expected at $130.27 by July 31, 2025, within a range of $123.65 to $136.29 3-Month Outlook: Projected fall of -59.08%, reaching $52.97 by October 15, 2025, with a range of $42.56 to $58.38. 1-Year Outlook: Projected gain of 13.22%, with price at $146.58 by July 17, 2026, within a range of $140.64 to $151.71.

Key Takeaways

Blueprint Medicines Corporation (NASDAQ:BPMC) shares are up 48.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Blueprint Medicines Corporation trading at a premium to the broader market with a P/E of -166.47. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $100.19, suggesting -22.61% downside. Our AI forecast model points to short-term strength (0.63% over two weeks), a medium-term fall (-59.08% over three months), and a longer-term gain (13.22% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Blueprint Medicines Corporation (BPMC) stock price?

Blueprint Medicines Corporation (NASDAQ: BPMC) stock price is $129.46 in the last trading session. During the trading session, BPMC stock reached the peak price of $129.46 while $129.46 was the lowest point it dropped to. The percentage change in BPMC stock occurred in the recent session was 0.14% while the dollar amount for the price change in BPMC stock was $0.18.

BPMC's industry and sector of operation?

The NASDAQ listed BPMC is part of Biotechnology industry that operates in the broader Healthcare sector. Blueprint Medicines Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BPMC?

Ms. Debra Durso-Bumpus
Chief People Officer
Dr. Percy H. Carter M.B.A., Ph.D.
Chief Scientific Officer
Jenna Cohen
Senior Director & Head of Investor Relations
Mr. Michael Landsittel
Chief Financial Officer
Mr. Alexis A. Borisy A.M.
Founder & Executive Chairman of Board of Directors
Ms. Tracey L. McCain Esq.
Executive Vice President, Chief Legal & Compliance Officer and Sec.
Mr. Jeffrey W. Albers J.D., M.B.A., MBA
Executive Chairman
Ms. Christina Rossi
Chief Operating Officer
Dr. Christopher K. Murray
Senior Vice President of Technical Operations
Dr. Christopher K. Murray Ph.D.
Senior Vice President of Technical Operations and Chief Technical Operations & Quality Officer
Ms. Ariel Hurley
Senior Vice President, Fin. & Principal Accounting Officer
Ms. Kathryn Haviland
Pres, Chief Executive Officer & Director

How BPMC did perform over past 52-week?

BPMC's closing price is 77.25% higher than its 52-week low of $73.04 where as its distance from 52-week high of $129.55 is -0.07%.

How many employees does BPMC have?

Number of BPMC employees currently stands at 682.

Link for BPMC official website?

Official Website of BPMC is: https://www.blueprintmedicines.com

How do I contact BPMC?

BPMC could be contacted at phone 617 374 7580 and can also be accessed through its website. BPMC operates from 45 Sidney Street, Cambridge, MA 02139, United States.

How many shares of BPMC are traded daily?

BPMC stock volume for the day was 2.98M shares. The average number of BPMC shares traded daily for last 3 months was 3.29M.

What is the market cap of BPMC currently?

The market value of BPMC currently stands at $8.36B with its latest stock price at $129.46 and 64.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	682
Beta	0.83
Sales or Revenue	$249.38M
5Y Sales Change%	3.058%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

BPMC Company Profile and Key Details

Blueprint Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics